Clinical Trial

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with sacituzumab govitecan (SG), in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2021-03-09; most recent amendment 2026-04-06.
Status change: Recruiting → Active, Not Recruiting 2026-04-06
Trial Details
NCT Number NCT04794699
Lead Sponsor IDEAYA Biosciences
Conditions Solid Tumor
Enrollment 169 participants
Start Date 2021-04-14
Primary Completion 2027-01-07 (estimated)
Study Completion 2027-02-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-09